Radial-EBUS and virtual bronchoscopy planner for peripheral lung cancer diagnosis: How it became the first-line endoscopic procedure.
bronchoscopy
lung cancer
peripheral pulmonary nodule
radial endobronchial ultrasound
virtual bronchoscopy planner
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
12
08
2022
received:
21
07
2022
accepted:
13
08
2022
pubmed:
3
9
2022
medline:
19
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Various advanced bronchoscopy methods have been developed to reach peripheral lung lesions (PLL). In a large cohort, we aimed to assess a standardized procedure of first-line radial-endobronchial ultrasound (r-EBUS) and virtual bronchoscopy planner for the diagnosis of peripheral lung cancer. This retrospective, single center study included patients who had r-EBUS-guided bronchoscopy for the diagnosis of a PLL between 2008 and 2019. Cases without a final diagnosis of cancer or follow-up were excluded. Between 2008 and 2019, 2735 patients had a r-EBUS procedure, among whom 1627 had a final diagnosis of cancer and were included in the present study. Over the 12-year study period, r-EBUS became the first-line endoscopic procedure to assess PLL (25% as first-line bronchoscopy in 2008 vs. 92% in 2019). The frequency of the bronchus sign decreased from 2009 to 2019 (100% to 80%; p = 0.001), whereas US visualization of the lesion remained stable (88%). The median number of biopsies increased from two (2008 to 2014) to four (2015 to 2019) (p < 0.0001), with the same diagnostic efficiency (74% total and 80% when a bronchus sign was present). Of the 651 adenocarcinomas, molecular analysis was possible in 86%. PD-L1 expression analysis was possible in 81% of cases. During the study period, the lifetime of the radial probe increased from 57 procedures to 77 procedures/probe. Because r-EBUS and VB planner is easy to perform under local anesthesia, inexpensive and efficient it can be used as a first-line procedure to assess peripheral lung cancer.
Sections du résumé
BACKGROUND
Various advanced bronchoscopy methods have been developed to reach peripheral lung lesions (PLL). In a large cohort, we aimed to assess a standardized procedure of first-line radial-endobronchial ultrasound (r-EBUS) and virtual bronchoscopy planner for the diagnosis of peripheral lung cancer.
METHODS
This retrospective, single center study included patients who had r-EBUS-guided bronchoscopy for the diagnosis of a PLL between 2008 and 2019. Cases without a final diagnosis of cancer or follow-up were excluded.
RESULTS
Between 2008 and 2019, 2735 patients had a r-EBUS procedure, among whom 1627 had a final diagnosis of cancer and were included in the present study. Over the 12-year study period, r-EBUS became the first-line endoscopic procedure to assess PLL (25% as first-line bronchoscopy in 2008 vs. 92% in 2019). The frequency of the bronchus sign decreased from 2009 to 2019 (100% to 80%; p = 0.001), whereas US visualization of the lesion remained stable (88%). The median number of biopsies increased from two (2008 to 2014) to four (2015 to 2019) (p < 0.0001), with the same diagnostic efficiency (74% total and 80% when a bronchus sign was present). Of the 651 adenocarcinomas, molecular analysis was possible in 86%. PD-L1 expression analysis was possible in 81% of cases. During the study period, the lifetime of the radial probe increased from 57 procedures to 77 procedures/probe.
CONCLUSION
Because r-EBUS and VB planner is easy to perform under local anesthesia, inexpensive and efficient it can be used as a first-line procedure to assess peripheral lung cancer.
Identifiants
pubmed: 36054681
doi: 10.1111/1759-7714.14629
pmc: PMC9575082
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2854-2860Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
BMC Pulm Med. 2018 Aug 13;18(1):137
pubmed: 30103727
Eur Respir J. 2013 Mar;41(3):539-47
pubmed: 22835609
PLoS One. 2018 Jan 22;13(1):e0191590
pubmed: 29357388
Sci Rep. 2018 Apr 11;8(1):5837
pubmed: 29643378
Thorac Cancer. 2022 Oct;13(20):2854-2860
pubmed: 36054681
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Chest. 2018 Feb;153(2):387-394
pubmed: 28847547
BMC Pulm Med. 2017 Dec 11;17(1):184
pubmed: 29228929
J Thorac Oncol. 2022 Apr;17(4):519-531
pubmed: 34973418
Eur Radiol. 2017 Jan;27(1):138-148
pubmed: 27108299
PLoS One. 2019 Feb 26;14(2):e0212672
pubmed: 30807604
BMC Cancer. 2019 Jun 7;19(1):546
pubmed: 31174496
Respirology. 2017 Apr;22(3):443-453
pubmed: 28177181
Am J Respir Crit Care Med. 2007 Jul 1;176(1):36-41
pubmed: 17379850
Chest. 2012 Aug;142(2):377-384
pubmed: 22302298
BMC Pulm Med. 2019 Oct 31;19(1):193
pubmed: 31672128
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Cancer Cytopathol. 2020 May;128(5):333-340
pubmed: 31995670
Chest. 2020 Mar;157(3):694-701
pubmed: 31678307
Respirology. 2016 May;21(4):718-26
pubmed: 27099101
Am J Respir Crit Care Med. 2016 Jan 1;193(1):68-77
pubmed: 26367186
Chest. 2000 Apr;117(4):1049-54
pubmed: 10767238
Eur Respir J. 2004 Oct;24(4):533-7
pubmed: 15459129
Chest. 2020 Apr;157(4):994-1011
pubmed: 31738928
Respirology. 2020 Sep;25(9):914-923
pubmed: 32103596
Respir Investig. 2021 Nov;59(6):766-771
pubmed: 33992599
Chest. 2006 Jan;129(1):147-50
pubmed: 16424425
BMC Pulm Med. 2021 Oct 16;21(1):322
pubmed: 34656103